Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers

Background: Kits (combinations of immune-modulatory compounds: GM-CSF+Picibanil (Kit-I), Prostaglandine (PG-E2,Kit-K) or +PGE1 (Kit-M), patent 102014014993) convert myeloid blasts into dendritic cells of leukemic origin (DCleu). After stimulation with DCleu, antileukemic T-cells can be generated ex vivo. Compounds are approved for clinical use and are attractive tools for immunotherapy in myeloid leukemia.